Barrington Keeps Their Buy Rating on Opko Health (OPK)

By Jason Carr

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Opko Health (OPKResearch Report), with a price target of $4.00. The company’s shares closed last Monday at $1.40, close to its 52-week low of $1.33.

According to, Petusky is a 3-star analyst with an average return of 2.0% and a 48.4% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Merit Medical Systems, and Anika Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for Opko Health.

See today’s analyst top recommended stocks >>

Based on Opko Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $112 million. In comparison, last year the company had a GAAP net loss of $76.07 million.

Based on the recent corporate insider activity of 89 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPK in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations.